The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia
Open Access
- 1 January 2015
- journal article
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 58 (9) , 347-353
Abstract
The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD). The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study. The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30 [43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414). Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.Keywords
Funding Information
- Korea Food and Drug Administration
This publication has 33 references indexed in Scilit:
- Incidence of Bronchopulmonary Dysplasia in KoreaJournal of Korean Medical Science, 2012
- Targeting Inflammation to Prevent Bronchopulmonary Dysplasia: Can New Insights Be Translated Into Therapies?Pediatrics, 2011
- Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research NetworkPediatrics, 2010
- Safety and tolerability of montelukast in placebo‐controlled pediatric studies and their open‐label extensionsPediatric Pulmonology, 2009
- Patterns of Respiratory Disease During the First 2 Postnatal Weeks in Extremely Premature InfantsPediatrics, 2009
- Differential Responses in the Lungs of Newborn Mouse Pups Exposed to 85% or >95% OxygenPediatric Research, 2009
- Montelukast as an add-on therapy in bronchopulmonary dysplasiaKorean Journal of Pediatrics, 2009
- Pharmacokinetics and Safety of Montelukast Oral Granules in Children 1 to 3 Months of Age With BronchiolitisThe Journal of Clinical Pharmacology, 2008
- Montelukast in the Treatment of Allergic RhinitisDrugs, 2007
- Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 yearsClinical & Experimental Allergy, 2001